

Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

CD19 Antibody, anti-human, VioBlue®, REAfinity™

RRID:AB_2784030

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-120-031, RRID:AB_2784030

Antibody Information

URL: http://antibodyregistry.org/AB_2784030

Proper Citation: Miltenyi Biotec Cat# 130-120-031, RRID:AB_2784030

Target Antigen: CD19

Host Organism: human

Clonality: monoclonal

Antibody Name: CD19 Antibody, anti-human, VioBlue®, REAfinity™

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: clone REA675

Antibody ID: AB_2784030

Vendor: Miltenyi Biotec

Catalog Number: 130-120-031

Record Creation Time: 20231110T032955+0000

Record Last Update: 20260901T020844+0000

Ratings and Alerts

No rating or validation information has been found for CD19 Antibody, anti-human, VioBlue®, REAfinity™.

No alerts have been found for CD19 Antibody, anti-human, VioBlue®, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Calaud C, et al. (2026) Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. Blood neoplasia, 3(2), 100214.

Krug A, et al. (2024) Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. Journal of experimental & clinical cancer research : CR, 43(1), 43.